Skin cancer, as the most physically accessible malignancy, provides for the most therapeutic diversity. The life expectancy of people diagnosed with malignant melanoma has increased dramatically during the previous two decades. However, there are still numerous situations when illness outnumbers traditional therapy, and those patients must rely on their inventiveness to survive. Drugs that can be injected directly into patients’ tumours have become more promising, not least because of the decrease in adverse effects reported. Intratumoral treatment includes a diverse range of medicines, ranging from chemotherapeutic medications to cancer vaccines. While each has some effectiveness, medicines that control the immune system have the best chance of avoiding disease development or recurrence. Recent study has underlined the necessity of having cytotoxic T cells present as well as keeping regulatory T cells in control. 

As a result, altering the tumour microenvironment is a requirement in skin cancer therapy that intratumoral administration may be able to solve. More research is needed to test intralesional medicines in conjunction with presently authorised therapy and with each other in order to discover the optimal approach for each person’s condition.